Type 1 And Type 2 Diabetic Patients Display Different Patterns of Cellular Microparticles

  1. Florence Sabatier12,
  2. Patrice Darmon3,
  3. Benedicte Hugel4,
  4. Valery Combes12,
  5. Marielle Sanmarco2,
  6. Jean-Gabriel Velut5,
  7. Dominique Arnoux2,
  8. Phillipe Charpiot1,
  9. Jean-Marie Freyssinet4,
  10. Charles Oliver3,
  11. Jose Sampol12 and
  12. Francoise Dignat-George12
  1. 1INSERM EMI 0019, Laboratory of Immunology and Hematology, UFR de Pharmacie, Université de la Méditerranée, Marseille, France
  2. 2Federation of Autoimmunity and Thrombosis, AP-HM de la Conception, Marseille, France
  3. 3Department of Endocrinology, Metabolic Diseases and Nutrition, AP-HM Nord, Marseille, France
  4. 4Institute of Hematology and Immunology, Faculty of Medicine, Strasbourg, France
  5. 5Department of Internal Medicine, AP-HM Nord, Marseille, France


    The development of vasculopathies in diabetes involves multifactorial processes including pathological activation of vascular cells. Release of microparticles by activated cells has been reported in diseases associated with thrombotic risk, but few data are available in diabetes. The aim of the present work was to explore the number and the procoagulant activity of cell-derived microparticles in type 1 and 2 diabetic patients. Compared with age-matched control subjects, type 1 diabetic patients presented significantly higher numbers of platelet and endothelial microparticles (PMP and EMP), total annexin V-positive blood cell microparticles (TMP), and increased levels of TMP-associated procoagulant activity. In type 2 diabetic patients, only TMP levels were significantly higher without concomitant increase of their procoagulant activity. Interestingly, in type 1 diabetic patients, TMP procoagulant activity was correlated with HbA1c, suggesting that procoagulant activity is associated with glucose imbalance. These results showed that a wide vesiculation process, resulting from activation or apoptosis of several cell types, occurs in diabetes. However, diabetic patients differ by the procoagulant activity and the cellular origin of microparticles. In type 1 diabetic patients, TMP-procoagulant activity could be involved in vascular complications. Moreover, its correlation with HbA1c reinforces the importance of an optimal glycemic control in type 1 diabetes.


    • Address correspondence and reprint requests to Professor Françoise Dignat-George, INSERM EMI 0019, Laboratory of Immunology and Hematology, UFR de Pharmacie, Université de la Méditerranée, 27 Bd Baille, Marseille, France. E-mail: dignat{at}pharmacie.univ-mrs.fr.

      Received for publication 31 October 2001 and accepted in revised form 4 June 2002.

      EMP, endothelial microparticle; FITC, fluorescein isothyocyanate; mAb, monoclonal antibody; PE, phycoerythrine; PMP, platelet microparticle; TMP, total annexin V-positive blood cell microparticle; TNF, tumor necrosis factor.

    | Table of Contents